The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Longterm Safety of Patients Receiving Rituximab in Rheumatoid Arthritis Clinical Trials
Open accessAbstract
Objective.: To evaluate the longterm safety of rituximab in clinical trials in patients with rheumatoid arthritis (RA). Methods.: Pooled analysis of safety data, including adverse events (AE) and infections, from patients treated with rituximab in combination with methotrexate in a global clinical trial program. Results.: A total of 2578 patients with RA received at least 1 course of rituximab. Safety analyses were based on 5013 patient-years of rituximab exposure. The most frequent AE was infusion-related reactions (25% of patients during the first infusion of Course 1). Less than 1% of infusion-related reactions were considered serious. Rates of AE and serious AE (SAE; 17.85 events/100 patient-yrs, 95% CI 16.72, 19.06) were stable following each course. The overall serious infection rate was 4.31/100 patient-years (95% CI 3.77, 4.92). Infections and serious infections over time remained stable across 5 courses at 4–6 events/100 patient-years. Compared with other patients with RA and with the general US population, there was no increased risk of malignancy. Conclusion.: In this longterm safety update in RA clinical trial patients, rituximab remained well tolerated over multiple courses. SAE and infections remained stable over time and by treatment course.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
Self-citationBongartz, T., Sutton, A. J., Sweeting, M. J., Buchan, I., Matteson, E. L., & Montori, V. (2006) · JAMA · doi:10.1001/jama.295.19.2275 · Cited by 2,468
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Maloney, D. G., Grillo-López, A. J., White, C. A., Bodkin, D., Schilder, R. J., Neidhart, J. A., Janakiraman, N., Foon, K. A., Liles, T.-M., Dallaire, B. K., et al. (1997) · Blood · doi:10.1182/blood.v90.6.2188 · Cited by 1,733
Cohen, S. B., Emery, P., Greenwald, M. W., Dougados, M., Furie, R. A., Genovese, M. C., Keystone, E. C., Loveless, J. E., Burmester, G., Cravets, M. W., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22025 · Cited by 1,638
Self-citationEmery, P., Fleischmann, R., Filipowicz‐Sosnowska, A., Schechtman, J., Szczepanski, L., Kavanaugh, A., Racewicz, A. J., van Vollenhoven, R. F., Li, N. F., Agarwal, S., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21778 · Cited by 1,060
Self-citationBaecklund, E., Iliadou, A., Askling, J., Ekbom, A., Backlin, C., Granath, F., Catrina, A. I., Rosenquist, R., Feltelius, N., Sundström, C., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21675 · Cited by 890
Dixon, W. G., Watson, K. D., Lunt, M., Hyrich, K. L., Silman, A. J., & Symmons, D. P. M. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22809 · Cited by 562
Rituximab in relapsing‐remitting multiple sclerosis: A 72‐week, open‐label, phase I trial
Bar‐Or, A., Calabresi, P. A. J., Arnold, D., Markowitz, C., Shafer, S., Kasper, L. H., Waubant, E., Gazda, S., Fox, R. J., Panzara, M., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21363 · Cited by 527
Practice parameter for the diagnosis and management of primary immunodeficiency
Bonilla, F. A., Bernstein, I. L., Khan, D. A., Ballas, Z. K., Chinen, J., Frank, M. M., Kobrynski, L. J., Levinson, A. I., Mazer, B., Nelson, R. P., et al. (2005) · Annals of Allergy, Asthma & Immunology · doi:10.1016/s1081-1206(10)61142-8 · Cited by 521
Maini, R. N., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Furst, D., Weisman, M. H., St.Clair, E. W., Keenan, G. F., van der Heijde, D., Marsters, P. A., et al. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20159 · Cited by 514
Self-citationA meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis
Smitten, A. L., Simon, T. A., Hochberg, M. C., & Suissa, S. (2008) · Arthritis Research & Therapy · doi:10.1186/ar2404 · Cited by 474
Patterns of cardiovascular risk in rheumatoid arthritis
Solomon, D. H., Goodson, N. J., Katz, J. N., Weinblatt, M. E., Avorn, J., Setoguchi, S., Canning, C., & Schneeweiss, S. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.050377 · Cited by 412
Schiff, M. H., Burmester, G. R., Kent, J. D., Pangan, A. L., Kupper, H., Fitzpatrick, S. B., & Donovan, C. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.043166 · Cited by 390
Rheumatoid arthritis and cancer risk
Mellemkjær, L., Linet, M. S., Gridley, G., Frisch, M., Møller, H., & Olsen, J. H. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(96)00210-9 · Cited by 383
Wolfe, F., & Michaud, K. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.09.039 · Cited by 372
Wolfe, F., & Michaud, K. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22579 · Cited by 348
Keystone, E., Fleischmann, R., Emery, P., Furst, D. E., van Vollenhoven, R., Bathon, J., Dougados, M., Baldassare, A., Ferraccioli, G., Chubick, A., et al. (2007) · Arthritis & Rheumatism · doi:10.1002/art.23059 · Cited by 337
Self-citationSerious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy
Kroesen, S. (2003) · Rheumatology · doi:10.1093/rheumatology/keg263 · Cited by 328
Smitten, A. L., Choi, H. K., Hochberg, M. C., Suissa, S., Simon, T. A., Testa, M. A., & Chan, K. A. (2007) · Arthritis Care & Research · doi:10.1002/art.23112 · Cited by 281
Genovese, M. C., Schiff, M., Luggen, M., Becker, J.-C., Aranda, R., Teng, J., Li, T., Schmidely, N., Le Bars, M., & Dougados, M. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.074773 · Cited by 264
Burmester, G. R., Xavier Mariette, A., Montecucco, C., Sáez, I. M., Malaise, M., Tzioufas, A. G., Bijlsma, J. W. J., Unnebrink, K., Kary, S., & Küpper, H. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.066761 · Cited by 202
Kremer, J. M., Genant, H. K., Moreland, L. W., Russell, A. S., Emery, P., Abud‐Mendoza, C., Szechiński, J., Li, T., Teng, J., Becker, J., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23397 · Cited by 174
Self-citationImmunohistochemical analysis as a means to predict responsiveness to rituximab treatment
Teng, Y. K. O., Levarht, E. W. N., Hashemi, M., Bajema, I. M., Toes, R. E. M., Huizinga, T. W. J., & van Laar, J. M. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22967 · Cited by 171
Immunology, immunopathology and immunity
Sell, S. (1973) · Arthritis & Rheumatism · doi:10.1002/art.1780160224 · Cited by 158
Specific Humoral Immunity in the Elderly: in vivo and in vitro Response to Vaccination
Burns, E. A., Lum, L. G., L'Hommedieu, G. D., & Goodwin, J. S. (1993) · Journal of Gerontology · doi:10.1093/geronj/48.6.b231 · Cited by 154
Wolfe, F., Michaud, K. D., & Chakravarty, E. F. (2006) · Lara D. Veeken · doi:10.1093/rheumatology/kel328 · Cited by 153
Genovese, M. C., Bathon, J. M., Fleischmann, R., Moreland, L. W., Martin, R. W., Whitmore, J. B., Tsuji, W. H., & Leff, J. A. (2005) · PubMed · Cited by 135
Self-citationMolloy, E. S., & Calabrese, L. H. (2008) · Autoimmunity Reviews · doi:10.1016/j.autrev.2008.07.006 · Cited by 127
Moreland, L. W., Weinblatt, M. E., Keystone, E. C., Kremer, J. M., Martin, R. W., Schiff, M. H., Whitmore, J. B., & White, B. (2006) · PubMed · Cited by 117
Self-citationSafety of Biologic Therapy in Rheumatoid Arthritis and Other Autoimmune Diseases: Focus on Rituximab
Fleischmann, R. (2008) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2008.01.001 · Cited by 65
Self-citationSell, S., & Max, E. E. (2001) · doi:10.1128/9781555818012.ch4 · Cited by 6
(2008) · PubMed
Cited by
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
Furst, D. E., Keystone, E. C., Braun, J., Breedveld, F. C., Burmester, G. R., De Benedetti, F., Dörner, T., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146852 · Cited by 687
Self-citationRituximab for the Treatment of IgG4-Related Disease: Lessons From 10 Consecutive Patients
Khosroshahi, A., Carruthers, M. N., Deshpande, V., Unizony, S., Bloch, D. B., & Stone, J. H. (2012) · Medicine · doi:10.1097/md.0b013e3182431ef6 · Cited by 489
Bingham, C. O., Looney, R. J., Deodhar, A., Halsey, N., Greenwald, M., Codding, C., Trzaskoma, B., Martin, F., Agarwal, S., & Kelman, A. (2010) · Arthritis & Rheumatism · doi:10.1002/art.25034 · Cited by 459
Self-citationUpdated consensus statement on the use of rituximab in patients with rheumatoid arthritis
Buch, M. H., Smolen, J. S., Betteridge, N., Breedveld, F. C., Burmester, G., Dörner, T., Ferraccioli, G., Gottenberg, J.-E., Isaacs, J., Kvien, T. K., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.144998 · Cited by 453
Self-citationvan Vollenhoven, R. F., Emery, P., Bingham, C. O., Keystone, E. C., Fleischmann, R. M., Furst, D. E., Tyson, N., Collinson, N., & Lehane, P. B. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-201956 · Cited by 390
Self-citation
Metadata
- Authors
- van VOLLENHOVEN, R. F., EMERY, P., BINGHAM, C. O., KEYSTONE, E. C., FLEISCHMANN, R., FURST, D. E., MACEY, K., SWEETSER, M., KELMAN, A., & RAO, R.
- Venue
- The Journal of Rheumatology
- Publisher
- The Journal of Rheumatology
- Published
- 2010-01-28
- Volume
- 37
- Issue
- 3
- Pages
- 558-567
- ISSN
- 0315-162X (ISSN-L)
- 1499-2752
- OpenAlex
- W2106997293
- Cited by
- 287
- References
- 33
- FWCI
- 24.49
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.